Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANDRAS HECZEY and DAVID STEFFIN.
ANDRAS HECZEY
Connection Strength
2.314
DAVID STEFFIN
  1. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
    View in: PubMed
    Score: 0.983
  2. Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. 2024 Apr 03.
    View in: PubMed
    Score: 0.939
  3. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
    View in: PubMed
    Score: 0.208
  4. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Feb 17.
    View in: PubMed
    Score: 0.062
  5. Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Jan 20; e31557.
    View in: PubMed
    Score: 0.062
  6. Eighteen-year survival after GD2-directed Chimeric Antigen Receptor-Modified Immune Effector Cell Treatment for Neuroblastoma. Res Sq. 2024 Apr 11.
    View in: PubMed
    Score: 0.059
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.